Comparative Pharmacology
Head-to-head clinical analysis: MEPROBAMATE AND ASPIRIN versus PRASUGREL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEPROBAMATE AND ASPIRIN versus PRASUGREL.
MEPROBAMATE AND ASPIRIN vs PRASUGREL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Meprobamate is a carbamate derivative that acts as a CNS depressant, potentiating GABA-A receptor activity and inhibiting polysynaptic spinal reflexes. Aspirin irreversibly acetylates cyclooxygenase-1 and -2 (COX-1/2), inhibiting prostaglandin and thromboxane synthesis, resulting in analgesic, antipyretic, anti-inflammatory, and antiplatelet effects.
Prasugrel is a thienopyridine prodrug that irreversibly inhibits the P2Y12 receptor on platelets, blocking ADP binding and preventing platelet aggregation.
Aspirin 325 mg and meprobamate 200 mg orally every 6 to 8 hours as needed for pain or anxiety. Maximum daily dose: aspirin 3.9 g, meprobamate 1.6 g.
60 mg orally once daily as a loading dose, then 10 mg orally once daily maintenance
None Documented
None Documented
Clinical Note
moderatePrasugrel + Tranilast
"Prasugrel may increase the anticoagulant activities of Tranilast."
Clinical Note
moderatePrasugrel + Resveratrol
"Prasugrel may increase the anticoagulant activities of Resveratrol."
Clinical Note
moderatePrasugrel + Nimesulide
"Prasugrel may increase the anticoagulant activities of Nimesulide."
Clinical Note
moderatePrasugrel + Epoprostenol
"Prasugrel may increase the antiplatelet activities of Epoprostenol."
Aspirin: 15-20 minutes (parent drug), but salicylate half-life is dose-dependent: 2-3 hours for low doses, 15-30 hours for high doses. Meprobamate: 6-17 hours (mean 10 hours), prolonged in overdose or hepatic impairment.
The active metabolite has a terminal elimination half-life of about 7 hours (range 2–15 hours). This corresponds to once-daily dosing. Prasugrel itself is rapidly hydrolyzed and has a half-life of about 2 hours.
Aspirin: Renal excretion of salicylates (75% as salicyluric acid, 10% as salicylic acid, 10% as phenolic glucuronide, 5% as acyl glucuronide). Meprobamate: Renal excretion (10-20% unchanged, 80-90% as hydroxylated metabolites) and biliary excretion (<5%).
Approximately 68% of the dose is excreted in urine as inactive metabolites, and 27% in feces. No significant renal excretion of parent drug.
Category D/X
Category A/B
NSAID / Antiplatelet
Antiplatelet